Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Arcutis Biotherapeutics (ARQT – Research Report) and Axsome Therapeutics (AXSM – Research Report).
Arcutis Biotherapeutics (ARQT)
Mizuho Securities analyst Uy Ear maintained a Hold rating on Arcutis Biotherapeutics on December 29 and set a price target of $4.00. The company’s shares closed last Tuesday at $3.43, close to its 52-week low of $1.76.
According to TipRanks.com, Ear is a 2-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Arcutis Biotherapeutics with a $10.60 average price target, which is a 234.4% upside from current levels. In a report issued on December 18, Goldman Sachs also maintained a Hold rating on the stock with a $6.00 price target.
See the top stocks recommended by analysts >>
Axsome Therapeutics (AXSM)
Mizuho Securities analyst Graig Suvannavejh maintained a Buy rating on Axsome Therapeutics on December 29 and set a price target of $90.00. The company’s shares closed last Tuesday at $77.06.
According to TipRanks.com, Suvannavejh is a 1-star analyst with an average return of
Axsome Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $119.29, representing a 51.8% upside. In a report issued on December 26, H.C. Wainwright also reiterated a Buy rating on the stock with a $180.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on ARQT:
- FDA Approves Arcutis’ ZORYVE® (roflumilast) Topical Foam, 0.3% for the Treatment of Seborrheic Dermatitis in Individuals Aged 9 Years and Older
- Arcutis Biotherapeutics announces FDA approval of NDA for ZORYVE topical foam
- Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- FDA Accepts Arcutis’ Supplemental New Drug Application for Roflumilast Cream 0.15% for the Treatment of Atopic Dermatitis in Adults and Children Down to Age 6
- Arcutis Biotherapeutics announces U.S. FDA accepted sNDA for roflumilast cream
